Vaxart, Inc. - Common Stock (VXRT)

Competitors to Vaxart, Inc. - Common Stock (VXRT)

AstraZeneca PLC

AstraZeneca is a major player in the vaccine market, offering a range of viral vector-based vaccines, notably for COVID-19. While Vaxart is pioneering oral vaccine delivery, AstraZeneca has the resources, experience, and global reach that allow them to quickly develop, produce, and distribute their vaccines. AstraZeneca's partnerships with various governments and health organizations further enhance its competitive positioning, making it difficult for Vaxart to establish itself in a similar market landscape.

Moderna, Inc. 

Moderna, Inc. holds a strong competitive position with its messenger RNA (mRNA) technology platform, which has proven effective in developing vaccines for infectious diseases, including COVID-19. While Vaxart focuses on oral vaccines utilizing its proprietary tablet delivery system, Moderna's emphasis on speed and efficiency in vaccine development gives it a significant edge. The company's established presence in the vaccine market and strong partnerships with governments and health organizations create barriers for Vaxart, making it challenging for them to gain market share in the vaccine sector.

Novavax, Inc. 

Novavax, Inc. competes with Vaxart primarily through its development of recombinant protein-based vaccines, which includes their COVID-19 vaccine candidate. Novavax benefits from extensive clinical trial experience and a robust pipeline of vaccines targeting various infectious diseases. Their established relationships with regulatory agencies, which facilitate quicker approvals for their candidates, provide them with an advantage over Vaxart, whose oral vaccine technology is less traditional and not yet proven in the market.

Seqirus (a division of CSL Limited)

Seqirus specializes in the development of seasonal influenza vaccines and has a strong market presence. The company leverages its expertise in vaccine production and distribution along with a well-established supply chain. While Vaxart focuses on innovative oral vaccine technology, Seqirus enjoys competitive advantages in terms of scale and established customer relationships. The established market share that Seqirus maintains in the influenza vaccine sector poses a challenge for Vaxart as it attempts to penetrate the vaccine landscape with its alternative methods.